Why You Cannot Treat an Investigational Drug Like an Approved Medicine

When a new weight-loss medicine posts big trial results, it can feel like it's basically here. But an investigational drug, one still being studied, isn't the same thing as an approved prescription medicine. Retatrutide and CagriSema are good examples: as of October 2026, both have strong trial data and neither is FDA-approved.

What approval adds

Before the FDA approves a medicine, it reviews the full clinical-trial evidence, the balance of benefits and risks, how the drug is manufactured and controlled for quality, and the proposed label. Approval doesn't mean a medicine is risk-free or right for everyone. It does mean there's an official label that spells out who it's for, how it's dosed, its warnings and what's known about side effects, plus a manufacturing process that's inspected and monitored.

Safety tracking continues after approval, too. Rare side effects sometimes only show up once many more people are using a medicine, which is why post-marketing monitoring matters.

Why a trial headline isn't enough

Drug development moves through phases. According to the FDA, Phase 1 studies typically involve 20 to 100 people and focus on safety and dosing; Phase 2 studies involve up to several hundred people and look at effectiveness and side effects; Phase 3 studies involve roughly 300 to 3,000 people over one to four years. Many drugs never make it through. Our guide to clinical trial phases explains what each stage can and can't tell you.

A company press release can arrive months before a full peer-reviewed paper, and it may highlight the most favorable analysis. Full publications and regulatory reviews add the details that matter, such as who dropped out and why, side effects by dose, and limitations.

The risk of buying "research" medicines

Vials and powders sold online under research-chemical names, often labeled "for research use only" or "not for human consumption," haven't been through any of that review. Their identity, concentration, sterility and dose are unverified, and they come without reliable instructions. The FDA has warned about unapproved GLP-1 products, including counterfeits that may contain the wrong ingredient or too much, too little or none of the active ingredient. A medical journal reported in October 2026 that unapproved versions of investigational drugs such as retatrutide are being sold online. Injecting a product from an unverified source isn't a safe shortcut.

Is there any legitimate way to access an investigational drug?

Two main routes exist in the US. The first is joining a clinical trial, which you can search for on ClinicalTrials.gov. The second is expanded access (sometimes called compassionate use). The FDA describes it as a pathway for people with a serious or life-threatening condition who have no comparable alternative and can't join a trial, requested through a physician and the drug's manufacturer. For example, Lilly opened a limited expanded-access program for retatrutide in August 2026. Either way, it happens under medical supervision, not by ordering online.

How to follow the pipeline safely

Use trial registries, peer-reviewed papers and official regulator announcements, and always check the date and country, because status changes. If you're interested in a future medicine, the best conversation is with a clinician about approved options available to you now, and whether a trial might be a fit, rather than trying to recreate a trial protocol at home.

Curiosity about what's coming is completely reasonable. Treating an unapproved product as ready to use isn't.